Goldman Sachs is saying good things about this blue chip stock. The post 1 big reason to buy CSL shares now appeared first on ...

RBC Capital analyst Craig Wong-Pan maintained a Hold rating on CSL (CMXHF – Research Report) on January 29 and set a price target of A$286.00.

Australia’s Therapeutic Goods Administration (TGA) has approved CSL Ltd.’s Andembry (garadacimab) for preventing recurrent ...

Goldman Sachs analyst Davinthra Thillainathan maintained a Buy rating on CSL (CMXHF – Research Report) today and set a price target of ...

CSL's estimated fair value is AU$408 based on ... 17% below our fair value estimate Does the January share price for CSL Limited (ASX:CSL) reflect what it's really worth? Today, we will estimate ...

CSL Recognized as Top Employer for Young People for Fourth Consecutive Year Third year cadets working on board a CSL ship.

Learn More CSL Ltd (ASX: CSL) stock had an underwhelming year in 2024. During the 12 months, the biotechnology giant's shares traded relatively flat and underperformed the market. While this is ...

CSL Finance Ltd (Formerly known Consolidated Securities Limited) was incorporated on December 28, 1992. The Company is engaged in the business of providing the finance facilities to small and ...

Learn More If you have been thinking about buying CSL Ltd (ASX: CSL) shares, then read on. That's because Goldman Sachs has just named another reason to buy the biotechnology giant's shares.